Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Barrett's esophagus (a condition affecting the lining of the food pipe), either without any abnormal cell changes, or with suspected or confirmed abnormal cell changes ranging from mild to severe, or with an early-stage cancer in the food pipe
- You are scheduled for an examination or treatment procedure using a camera inserted into the food pipe (an endoscopy)
- You are willing and able to sign a written consent form agreeing to take part
Who may not be able to join:
- You are under 18 years of age
- Your esophageal (food pipe) cancer has spread deeper into the tissue or beyond, meaning it is not classified as an early-stage (T1) cancer
- You have previously had radiation therapy for esophageal (food pipe) cancer
- You have a known allergy to immunoglobulin (a type of protein used in some medicines) (confirm with trial site)
- You have previously had chemotherapy, immunotherapy, or related surgery
- You have previously been treated with the drugs bevacizumab or cetuximab
- You have a medical or mental health condition that affects your ability to fully understand and agree to take part in the trial
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wouter B. Nagengast, Prof. dr., University Medical Center Groningen
Phone: +31(0)503615755
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of shortening qFME procedural time by oral administration of bevacizumab-800CW and cetuximab-800CW for the detection of BE neoplasia.; Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.